Nabriva Therapeutics market cap is $50.1 m, and annual revenue was $5.03 m in FY 2020

Nabriva Therapeutics Gross profit (Q1, 2021)2.5 M

Nabriva Therapeutics Gross profit margin (Q1, 2021), %97.5%

Nabriva Therapeutics Net income (Q1, 2021)-14 M

Nabriva Therapeutics EBIT (Q1, 2021)-13.4 M

Nabriva Therapeutics Cash, 31-Mar-202154.8 M

Nabriva Therapeutics EV3.1 M

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Revenue | 9.7m | 9.5m | 5.0m | ||

## Cost of goods sold | 70.0k | 766.0k | |||

## Gross profit | 9.4m | 4.3m | |||

| 99% | 85% | |||

## Operating expense total | 88.9m | 70.4m | |||

## EBIT | (55.0m) | (73.8m) | (114.4m) | (79.5m) | (66.1m) |

| (1184%) | (838%) | (1315%) | ||

## Interest expense | 783.0k | 43.0k | |||

## Interest income | 343.0k | 318.0k | 49.0k | 255.0k | 86.0k |

## Pre tax profit | (55.6m) | (73.0m) | (114.7m) | (82.7m) | (69.3m) |

## Income tax expense | (672.0k) | 1.4m | 49.0k | 101.0k | 139.0k |

## Net Income | (54.9m) | (74.4m) | (114.8m) | (82.8m) | (69.5m) |

USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 7.6m | 847.0k | 461.0k | 1.7m | 525.0k | 6.9m | 789.0k | 1.3m | 2.5m | |||

## Cost of goods sold | 15.0k | 8.0k | 25.0k | 62.0k | ||||||||

## Gross profit | 6.9m | 781.0k | 1.3m | 2.5m | ||||||||

| 100% | 99% | 98% | 98% | ||||||||

## Operating expense total | 24.1m | 21.0m | 14.5m | 15.9m | ||||||||

## EBIT | (15.2m) | (15.6m) | (20.7m) | (12.9m) | (17.7m) | (52.9m) | (19.2m) | (21.0m) | (17.2m) | (20.2m) | (13.2m) | (13.4m) |

| (170%) | (2091%) | (11480%) | (1130%) | (3995%) | (249%) | (2559%) | (1024%) | (532%) | |||

## Interest expense | 206.0k | 116.0k | 301.0k | 23.0k | 141.0k | |||||||

## Interest income | 121.0k | 112.0k | 69.0k | 9.0k | 19.0k | 11.0k | 10.0k | 72.0k | 94.0k | 64.0k | 5.0k | 1.0k |

## Pre tax profit | (14.9m) | (15.6m) | (20.4m) | (12.8m) | (17.8m) | (53.0m) | (20.1m) | (21.8m) | (17.8m) | (23.1m) | (13.0m) | (13.8m) |

## Income tax expense | 349.0k | (967.0k) | 1.9m | 506.0k | (48.0k) | (151.0k) | 154.0k | (45.0k) | (29.0k) | 152.0k | (72.0k) | 190.0k |

## Net Income | (15.2m) | (14.6m) | (22.3m) | (13.3m) | (17.8m) | (52.8m) | (20.2m) | (21.7m) | (17.8m) | (23.3m) | (13.0m) | (14.0m) |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Cash | 32.8m | 86.8m | 102.0m | 86.0m | 41.4m |

## Accounts Receivable | 2.7m | 3.9m | |||

## Prepaid Expenses | 1.2m | 1.6m | 1.2m | 1.2m | 5.9m |

## Inventories | 682.0k | 5.8m | |||

## Current Assets | 90.6m | 93.8m | 108.8m | 91.2m | 57.2m |

## PP&E | 519.0k | 1.3m | 1.1m | 2.5m | 768.0k |

## Total Assets | 93.2m | 95.8m | 110.4m | 94.1m | 58.4m |

## Accounts Payable | 2.6m | 5.1m | 3.3m | 4.7m | 2.9m |

## Short-term debt | 2.0m | ||||

## Current Liabilities | 15.9m | 13.3m | 17.8m | 16.6m | 18.5m |

## Long-term debt | 232.0k | 23.7m | 34.5m | 5.7m | |

## Non-Current Liabilities | 435.0k | 24.0m | 36.2m | 6.8m | |

## Total Debt | 232.0k | 23.7m | 34.5m | 7.7m | |

## Total Liabilities | 16.0m | 13.7m | 41.8m | 52.8m | 25.3m |

## Common Stock | 2.9m | 670.0k | 945.0k | 211.0k | |

## Additional Paid-in Capital | 279.1m | 360.9m | 461.9m | 517.0m | 579.1m |

## Retained Earnings | (204.8m) | (279.2m) | (394.0m) | (476.7m) | (546.2m) |

## Total Equity | 77.3m | 82.1m | 68.6m | 41.3m | 33.1m |

## Debt to Equity Ratio | 0 x | 0.3 x | |||

## Debt to Assets Ratio | 0 x | 0.2 x | |||

## Financial Leverage | 1.2 x | 1.2 x | 1.6 x | 2.3 x | 1.8 x |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Net Income | (54.9m) | (74.4m) | (114.8m) | (82.8m) | (69.5m) |

## Depreciation and Amortization | 233.0k | 432.0k | 510.0k | 396.0k | 417.0k |

## Accounts Receivable | (1.9m) | (223.0k) | 1.1m | ||

## Inventories | (682.0k) | (5.1m) | |||

## Accounts Payable | (383.0k) | 2.6m | (3.0m) | 1.3m | (1.8m) |

## Cash From Operating Activities | (49.3m) | (69.3m) | (72.7m) | (71.9m) | (71.3m) |

## Purchases of PP&E | (603.0k) | (1.2m) | (229.0k) | (61.0k) | (113.0k) |

## Cash From Investing Activities | 23.4m | 49.7m | (4.6m) | 331.0k | (274.0k) |

## Cash From Financing Activities | 22.3m | 72.2m | 92.9m | 56.1m | 26.9m |

## Net Change in Cash | (3.7m) | 54.0m | 15.2m | (15.6m) | (44.8m) |

## Interest Paid | 1.0k | 1.4m | |||

## Income Taxes Paid | 5.0k |

USD | FY, 2016 |
---|---|

## Financial Leverage | 1.2 x |